Keytruda
FDA Approves Keytruda for Biliary Cancer, Rivals AstraZeneca’s Imfinzi
Merck’s Keytruda has received FDA approval to treat locally advanced unresectable or metastatic biliary tract cancer, alongside gemcitabine and cisplatin ...
Keytruda: Merckās breakthrough cancer drug with mixed results at ESMO
Merck & Co. made significant strides at this year’s European Society for Medical Oncology (ESMO) congress, presenting a series of ...
KEYNOTE-671 Trial: Keytruda Sets New Standards in the Perioperative Treatment Landscape (ESMO 2023)
ESMO 2023: LBA56 Neoadjuvant NSCLC is a challenging market with few treatment options and many unmet needs. Merckās Keytruda is ...
Keytruda’s Success in KEYNOTE-756 Trial Ushers in a New Era for Early-Stage High-Risk ER+/HER2ā Breast Cancer Treatment (ESMO 2023)
ESMO 2023: LBA21 Keytruda (pembrolizumab) is a highly specific, human-made antibody that targets the PD-1 pathway and prevents cancer cells ...
ESMO 2023: GSKās Jemperli beats Merckās Keytruda in lung cancer survival trial
In a groundbreaking clinical trial, GSK has achieved remarkable patient survival results with its PD-1 inhibitor, Jemperli, when compared to ...
Keytruda approved by FDA for early-stage lung cancer surgery, with a twist
In a groundbreaking development, the FDA has granted approval for Merck’s Keytruda to be employed in a continuous immunotherapy regimen ...
Merckās Keytruda extends survival of early lung cancer patients in trial, awaits FDA approval
Merck & Co.’s Keytruda has achieved a groundbreaking milestone in the treatment landscape for early-stage non-small cell lung cancer (NSCLC), ...
Keytruda shows promise in bladder cancer trial, Merck says
Merck’s immunotherapy drug, Keytruda, continues to demonstrate success in the field of bladder cancer. After securing FDA approvals for use ...
Padcev-Keytruda combo cuts death risk in first-line bladder cancer
As Seagen readies itself for its impending acquisition by Pfizer, a significant triumph emerges for the company’s cancer drug Padcev, ...
Keytruda-Lenvima combo fails to improve survival in two lung cancer trials
Merck and Eisai’s collaborative effort with Keytruda and Lenvima faces yet another setback in their quest to combat cancer. Despite ...
Setbacks Continue: Merck and Eisai’s Ambitious Combo of Keytruda-Lenvima Stumble in Head and Neck Cancer Battle
In a somber development for the pharmaceutical world, Merck and Eisai find themselves facing yet another roadblock on their quest ...
Keytruda Gets Green Light from NHS for New Cancer āBasketā
MSD’s Keytruda (pembrolizumab) has secured a significant recommendation from the UK’s National Institute for Health and Care Excellence (NICE), signaling ...
Pembrolizumab Frontline Use With Lenvatinib Supported in nccRCC
Combining pembrolizumab (Keytruda) with lenvatinib (Lenvima) has showcased enduring effectiveness against tumors in patients with non-clear cell renal cell carcinoma ...
Mirati fires its CEO and announces a new lung cancer Krazati-Keytruda study strategy
Following the successful approval of the KRAS inhibitor Krazati, Mirati Therapeutics’ CEO David Meek has made an abrupt exit from ...
Even after buying Prometheus for $10.8 billion, Merck is still looking for M&A opportunities
Earlier this year, Merck’s acquisition of Prometheus Biosciences for $10.8 billion provided the New Jersey company with a much-needed diversification ...
Merck and Moderna Commence Phase III Study of V940 with KEYTRUDA for High-Risk Melanoma
Source – Merck Moderna and Merck announced the commencement of the pivotal Phase III randomized V940-001 clinical trial. This trial ...
KEYNOTE-A18 Trial: Primary Endpoint – Progression-Free Survival in High-Risk Cervical Cancer
Source – Merck Merck has announced a groundbreaking development in its Phase III KEYNOTE-A18 trial, also referred to as ENGOT-cx11/GOG-3047. ...
Pembrolizumab demonstrate effectiveness beyond five years as a first-line treatment for advanced NSCLC with PD-L1 expression
First-line treatment with pembrolizumab (Keytruda) has demonstrated long-term survival benefits and durable responses in patients with PD-L1-positive, locally advanced or ...
Merck’s Keytruda fails a study for early stomach cancer following metastatic disease victory
Source – Merck Inhibiting immune checkpoints hasn’t been very effective against stomach cancer. Merck has now added another failure to ...
Keytruda Triumphs: Promising Progression-Free Survival in HER2-Positive Gastric Cancer
Source: Merck Merck’s renowned cancer drug, Keytruda, may soon see an updated label for its effectiveness in treating HER2-positive stomach ...
